RxDoctor Payments Data

Rachel Glidden, APRN

Family · Columbus, NENPI 1447740642

Payments from drug & device makers

$462in general payments, 2019–2025

Across 23 payments — averaging $20.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$103
  • AbbVie$84
  • Novo Nordisk$72
  • Lilly USA, LLC$37
  • AstraZeneca$36
  • Amneal Pharmaceuticals LLC$25
  • plus $105 from 6 others

What the payments were for

  • Food & beverage$462100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$462 in reported general payments places this provider in the 60th percentile of 809 family providers in Nebraska.

See all family providers in Nebraska

Medicare billing

Part B allowed, 2024
$1,096
Medicare patients
18
Services billed
103

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol14$8,315
EliquisApixaban13$7,995
Advair DiskusFluticasone Propion/Salmeterol15$4,269
Ventolin HfaAlbuterol Sulfate28$1,731
Albuterol Sulfate HfaAlbuterol Sulfate29$907
Atorvastatin Calcium68$508
Omeprazole20$345
Levothyroxine Sodium37$337
Pantoprazole Sodium27$335
Metoprolol Succinate22$321
Alendronate Sodium21$281
Lisinopril-HydrochlorothiazideLisinopril/Hydrochlorothiazide19$267
Rosuvastatin Calcium22$243
Tizanidine Hcl16$234
Metformin Hcl46$232

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$36$8,31514 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$25$33737 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 809 family providers in Nebraska.

Other family in Columbus

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →